|
|
90% CI of the ratio |
1.54, 2.80 |
|
|
p-value** |
0.0005 |
|
AUC0-t (ng h mL-1) |
Estimated ratio
after inverse logarithmic conversion* |
2.02 |
|
|
90% CI of the ratio |
1.53, 2.67 |
|
|
p-value** |
0.0004 |
|
Tmax (h) |
Median (Min, Max) in carotegrast methyl
alone |
1.0 (0.5, 4.0) |
|
|
Median (Min, Max) in the combination with rifampicin |
2.0 (0.5,
4.0) |
|
|
Test statistics |
18.5 |
|
|
p-value** |
0.2847 |
|
t1/2 (h) |
Estimated ratio after inverse logarithmic
conversion* |
1.35 |
|
|
90% CI of the ratio |
1.12, 1.63 |
|
|
p-value** |
0.0112 |
|
MRT0-t (h) |
Estimated ratio after inverse logarithmic
conversion* |
1.05 |
|
|
90% CI of the ratio |
0.98, 1.14 |
|
|
p-value** |
0.2594 |
Carotegrast |
Cmax (ng mL-1) |
Estimated ratio after inverse logarithmic conversion* |
4.78 |
|
|
90% CI of the ratio |
3.64, 6.29 |
|
|
p-value** |
<.0001 |
|
AUC0-t (ng h mL-1) |
Estimated ratio
after inverse logarithmic conversion* |
5.59 |
|
|
90% CI of the ratio |
4.60, 6.79 |
|
|
p-value** |
<.0001 |
|
Tmax (h) |
Median (Min, Max) in carotegrast methyl
alone |
2.0 (1.0, 4.0) |
|
|
Median (Min, Max) in the combination with rifampicin |
4.0 (2.0,
4.0) |
|
|
Test statistics |
27.5 |
|
|
p-value** |
0.0020 |
|
t1/2 (h) |
Estimated ratio after inverse logarithmic
conversion* |
0.75 |
|
|
90% CI of the ratio |
0.58, 0.97 |
|
|
p-value** |
0.0677 |
|
MRT0-t (h) |
Estimated ratio after inverse logarithmic
conversion* |
1.13 |
|
|
90% CI of the ratio |
1.04, 1.22 |
|
|
p-value** |
0.0164 |
M-I |
Cmax (ng mL-1) |
Estimated ratio
after inverse logarithmic conversion* |
1.42 |
|
|
90% CI of the ratio |
1.15, 1.75 |
|
|
p-value** |
0.0094 |
|
AUC0-t (ng h mL-1) |
Estimated ratio
after inverse logarithmic conversion* |
1.58 |
|
|
90% CI of the ratio |
1.30, 1.92 |
|
|
p-value** |
0.0007 |
|
Tmax (h) |
Median (Min, Max) in carotegrast methyl
alone |
1.0 (0.5, 2.0) |
|
|
Median (Min, Max) in the combination with rifampicin |
1.0 (0.5,
4.0) |
|
|
Test statistics |
37.0 |
|
|
p-value** |
0.0348 |
|
t1/2 (h) |
Estimated ratio after inverse logarithmic
conversion* |
0.89 |
|
|
90% CI of the ratio |
0.70, 1.13 |
|
|
p-value** |
0.3877 |
|
MRT0-t (h) |
Estimated ratio after inverse logarithmic
conversion* |
1.09 |
|
|
90% CI of the ratio |
1.01, 1.19 |
|
|
p-value** |
0.0750 |
M-II |
Cmax (ng mL-1) |
Estimated
ratio after inverse logarithmic conversion* |
3.57 |
|
|
90% CI of the ratio |
2.91, 4.38 |
|
|
p-value** |
<.0001 |
|
AUC0-t (ng h mL-1) |
Estimated ratio
after inverse logarithmic conversion* |
6.05 |
|
|
90% CI of the ratio |
5.13, 7.14 |
|
|
p-value** |
<.0001 |
|
Tmax (h) |
Median (Min, Max) in carotegrast methyl
alone |
2.0 (1.0, 4.0) |
|
|
Median (Min, Max) in the combination with rifampicin |
4.0 (2.0,
6.0) |
|
|
Test statistics |
51.5 |
|
|
p-value** |
0.0010 |
|
t1/2 (h) |
Estimated ratio after inverse logarithmic
conversion* |
0.70 |
|
|
90% CI of the ratio |
0.63, 0.78 |
|
|
p-value (Treatment Group) |
<.0001 |
|
MRT0-t (h) |
Estimated ratio after inverse logarithmic
conversion |
1.49 |
|
|
90% CI of the ratio |
1.41, 1.57 |
|
|
p-value** |
<.0001 |
Carotegrast-glu |
Cmax (ng mL-1) |
Estimated ratio after inverse logarithmic conversion* |
0.79 |
|
|
90% CI of the ratio |
0.67, 0.94 |
|
|
p-value** |
0.0272 |
|
AUC0-t (ng h mL-1) |
Estimated ratio
after inverse logarithmic conversion* |
1.14 |
|
|
90% CI of the ratio |
0.99, 1.30 |
|
|
p-value** |
0.1158 |
|
Tmax (h) |
Median (Min, Max) in carotegrast methyl
alone |
2.0 (1.0, 4.0) |
|
|
Median (Min, Max) in the combination with rifampicin |
2.0 (1.0,
4.0) |
|
|
Test statistics |
11.0 |
|
|
p-value** |
0.1719 |
|
t1/2 (h) |
Estimated ratio after inverse logarithmic
conversion* |
0.98 |
|
|
90% CI of the ratio |
0.84, 1.14 |
|
|
p-value (Treatment Group) |
0.7938 |
|
MRT0-t (h) |
Estimated ratio after inverse logarithmic
conversion |
1.35 |
|
|
90% CI of the ratio |
1.26, 1.44 |
|
|
p-value** |
<.0001 |